Back to News
Oct 17, 2025 4:00 PM

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).

The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD).

cGVHD is considered one of the leading causes of morbidity and late non-relapse mortality after stem cell transplant. Sanofi will seek a re-examination of the CHMP opinion.

Also Read: Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

"We are disappointed by the negative CHMP opinion for ...